|Basilea Pharmaceutica AG -- USA Stock|| |
USD 68.16 0.000004 0.00%
Head - Corporate Development
We currently do not have informatin regarding Barbara Zink. This executive tanure with Basilea Pharmaceutica AG is not currenlty determined.
41 61 606 11 11 http://www.basilea.com
The company has return on total asset (ROA)
of (2.6) %
which means that it has lost $2.6 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (4.6) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 209.12 M in total debt. Basilea Pharmaceutica AG has Current Ratio of 3.62 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Basilea Pharmaceutica AG, together with its subsidiaries, operates as an integrated biopharmaceutical company. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland. Basilea Pharmaceutica is traded on OTC Market in USA.Basilea Pharmaceutica AG (BPMUF) is traded on OTC Market in USA. It is located in Grenzacherstrasse 487 and employs 230 people.